Debt to EBITDA ratio Analysis of Royalty Pharma Plc - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointDebt to EBITDA of RPRX
Dec-234.11Not Good Debt to EBITDA | Dec-2217.02Very Poor Debt to EBITDA | Growth-75.85% |
Debt to EBITDA Analysis of Royalty Pharma Plc
| Debt to EBITDA Ratio of RPRX drastically fell by -75.85 % this year. |
| Debt to EBITDA Ratio with value of 17.02 was highest in Year Dec-22 in last Five Years. |
| Debt to EBITDA Ratio with value of 0.253 was lowest in Year Dec-21 in last Five Years. |
| Latest Debt to EBITDA Ratio with value of 4.11 is lower than Average Debt to EBITDA of 5.81 in last five years. |
Other Debt to EBITDA Related Info of RPRX that may interest you.
Royalty Pharma Plc Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| RPRX | 27.41 | 26.39 | 3.87 % | Biotechnology |
Defination of Debt to EBITDA
The Debt to EBITDA Ratio is a solvency metric that measures the company's ability to meet its debt obligations by earnings before covering its interest, taxes, depreciation, and amortization. more ..
Debt to EBITDA Related Ratios
| CashFlowFromOperationToDebt | DebtToCapital | EVToEBITDA |
Tsr Stability Index
| Low Stability Stock | |
FY - Historical Debt to EBITDA of Royalty Pharma Plc
| Period | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 |
|---|---|---|---|---|---|---|---|
| Debt to EBITDA | 4.11 | 17.02 | 0.253 | 5.28 | 2.36 | 3.86 | 0 |
| Change | -75.85 % | 6636.73 % | -95.21 % | 123.51 % | -38.74 % |
FY Chart of Debt to EBITDA of Royalty Pharma Plc
Note : All Data Generated at the End of Trading Hours (EOD Data)